Close Menu

NEW YORK (GenomeWeb) – Cancer patients with a certain rare genetic variant may be more susceptible to developing treatment-induced cardiomyopathy, according to a new study.

While new cancer treatments have led to improved survival for many patients, they often come with side effects. Anthracyclines, which are used to treat both solid and hematological cancers, are linked to an increased risk of cardiotoxicity, for example, especially when combined with other drugs likes trastuzumab.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.